Valeria V. Nazarova

Valeria V. Nazarova

Auto-generated profile, based on publicly available information

Valeria V. Nazarova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2025 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
KOKristina Orlova
Kristina Orlova
MMMargarita V. Martynova
Margarita V. Martynova
NPNatalia N. Petenko
Natalia N. Petenko
VNValeria V. Nazarova
Valeria V. Nazarova
LDLev V. Demidov
Lev V. Demidov
Background. Basal cell skin carcinoma (BCSC) is the most common skin cancer. Most cases are diagnosed early and successfully treated using local methods. However, a small proportion of patients develop locally advanced or metastatic BCRCs, which is a challenging clinical issue. The number of locally advanced and/or metastatic forms of BCSCs is based on the experience of individual centers or the analysis of individual databases because the skin cancer cases generally are coded and accounted under the C44 category without counting separately the nosological forms and data on the disease prevalence. Aim. To estimate the number of patients with locally advanced and metastatic BCRCs among all patients treated in the N.N. Blokhin National Medical Research Center of Oncology from 2019 to July 2024 with the diagnosis code C44 according to the International Classification of Diseases, 10th Edition. Results. Between 2019 and July 2024, 3,801 individual cases of non-melanoma skin cancer (C44) were reported. Most of the 3,801 patients had BCSCs (n=2,796, 73.6%), followed by squamous cell carcinoma (n=857, 22.5%), Merkel cell carcinoma (n=100, 2.6%), and other skin tumors and neoplasms originating from the skin appendages (n=48, 1.3%). Among all cases of BCSCs, 94 (3.4%) cases of locally advanced and metastatic forms of the disease were reported. These patients were divided into two groups: with locally advanced BCSC (78 patients, 2.8%) and metastatic BCSC (16 patients, 0.6%). Conclusion. Most patients with early stages of BCSCs can be completely cured with radical surgery and/or radiation therapy, and a small number of patients develop disease progression that is not amenable to surgery or radiation therapy. We obtained the following results: 2.8% of locally advanced BCSCs and 0.6% of metastatic BCSCs, which is consistent with the literature data, where locally advanced BCSCs are reported in 1-2% of patients, and BCSC metastasis is reported in 0.0028-0.55%.

10 December 2021 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
AKAndrei Kaprin
Andrei Kaprin
VUV. M. Unguryan
V. M. Unguryan
LPL. O. Petrov
L. O. Petrov
SIS. A. Ivanov
S. A. Ivanov
YPYu. A. Pobedintseva
Yu. A. Pobedintseva
ЮПЮ. А. Побединцева
Ю. А. Побединцева
Introduction. Uveal melanoma is the most common primary intraocular tumor in adults. Despite some achievements in primary tumor treatment, 50% of patients develop distant metastases in various times (3 years to decades). Hematogenous spread is typical for uveal melanoma, and in 90% of the cases liver is the target. Median survival of patients with liver metastases is 4 to 9 months according to various researchers. And the result of treatment is extremely poor, unlike the results of skin melanoma treatment.The aim is to evaluate the immediate results of treatment of patients with uveal melanoma metastatic to the liver using isolated hepatic perfusion technique.Materials and methods. Considering a high risk of developing a metastatic liver disease in patients with uveal melanoma, local therapy is particularly interesting. This article describes the results of 10 metastatic uveal melanoma patients’ Isolated Hepatic Perfusion (IHP) Treatment. IHP was conducted using the standard methods with 100 mg of Melphalan for 60 min.Results and discussion. IHP treatment shows low complication rate. The data for response assessment is available on 9 out of 10 patients, because 10th patient received this treatment less than a month ago. Follow-ups a month after 9 patients underwent IHP showed an objective response to treatment in 6 patients (complete response in 1, partial response in 5 patients).Conclusion. The use of isolated liver chemoperfusion in a small group of patients according to the standard procedure allowed achieving an immediate response in 67% of cases.

1 January 2022 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
AKAndrei Kaprin
Andrei Kaprin
SIS.A. Ivanov
S.A. Ivanov
LPL.O. Petrov
L.O. Petrov
VKV.V. Kucherov
V.V. Kucherov
YPYu.A. Pobedintseva
Yu.A. Pobedintseva
VUV.M. Unguryan
V.M. Unguryan
ЦЕЛЬ СИСТЕМАТИЧЕСКОГО ОБЗОРА Сравнить методы трансартериальной химиоэмболизации и изолированной химиоперфузии печени путем оценки их безопасности, непосредственных и отдаленных результатов применения у больных с метастазами увеальной меланомы в печень. МАТЕРИАЛ И МЕТОДЫ Проведен систематический поиск литературы (базы данных PubMed, eLibrary, Cochrane Library) в соответствии с рекомендациями PRISMA 2020 (оформление чек-листа и построение блок-схемы), в результате отобраны 7 исследований. Критерии отбора клинических исследований следующие: метастазы увеальной меланомы в печень, трансартериальная химиоэмболизация, изолированная химиоперфузия печени. В качестве исходов выбраны такие показатели, как послеоперационная летальность, частота объективного ответа, общая выживаемость и безрецидивная выживаемость. В исследованиях, включенных в систематический обзор, изучаемые исходы анализировали при помощи построения кривых Каплана—Мейера. РЕЗУЛЬТАТЫ Частота объективного ответа, общая и безрецидивная выживаемость оказались статистически значимо выше у пациентов группы с применением изолированной химиоперфузии печени. При этом частота развития осложнений и послеоперационной летальности была статистически значимо ниже в группе с применением трансартериальной химиоэмболизации. ЗАКЛЮЧЕНИЕ Применение метода изолированной химиоперфузии является перспективным направлением в лечении больных с метастазами увеальной меланомы в печень. Следует рассмотреть возможность снижения частоты послеоперационных осложнений и летальности путем разработки минимально инвазивной техники выполнения изолированной перфузии печени.

20 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
GMGeorge Makiev
George Makiev
ISIgor Samoylenko
Igor Samoylenko
VNValeria V. Nazarova
Valeria V. Nazarova
ZMZakhra Magomedova
Zakhra Magomedova
ATAlexey Tryakin
Alexey Tryakin
TGTigran G. Gevorkyan
Tigran G. Gevorkyan
Background: The persistently low 5-year survival rate for pancreatic cancer (PC) underscores the critical need for early detection. However, population-wide screening remains impractical. Artificial Intelligence (AI) models using electronic health record (EHR) data offer a promising avenue for pre-symptomatic risk stratification. Objective: To systematically review and meta-analyze the performance of AI models for PC prediction based exclusively on structured EHR data. Methods: We systematically searched PubMed, MedRxiv, BioRxiv, and Google Scholar (2010–2025). Inclusion criteria encompassed studies using EHR-derived data (excluding imaging/genomics), applying AI for PC prediction, reporting AUC, and including a non-cancer cohort. Two reviewers independently extracted data. Random-effects meta-analysis was performed for AUC, sensitivity (Se), and specificity (Sp) using R software version 4.5.1. Heterogeneity was assessed using I2 statistics and publication bias was evaluated. Results: Of 946 screened records, 19 studies met the inclusion criteria. The pooled AUC across all models was 0.785 (95% CI: 0.759–0.810), indicating good overall discriminatory ability. Neural Network (NN) models demonstrated a statistically significantly higher pooled AUC (0.826) compared to Logistic Regression (LogReg, 0.799), Random Forests (RF, 0.762), and XGBoost (XGB, 0.779) (all p < 0.001). In analyses with sufficient data, models like Light Gradient Boosting (LGB) showed superior Se and Sp (99% and 98.7%, respectively) compared to NNs and LogReg, though based on limited studies. Meta-analysis of Se and Sp revealed extreme heterogeneity (I2 ≥ 99.9%), and the positive predictive values (PPVs) reported across studies were consistently low (often < 1%), reflecting the challenge of screening a low-prevalence disease. Conclusions: AI models using EHR data show significant promise for early PC detection, with NNs achieving the highest pooled AUC. However, high heterogeneity and typically low PPV highlight the need for standardized methodologies and a targeted risk-stratification approach rather than general population screening. Future prospective validation and integration into clinical decision-support systems are essential.

7 June 2022 in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
Verified
Journal Article
Open access
PDF file
AKAndrei Kaprin
Andrei Kaprin
SIS. A. Ivanov
S. A. Ivanov
VUV. M. Unguryan
V. M. Unguryan
LPL. O. Petrov
L. O. Petrov
VNV. V. Nazarova
V. V. Nazarova
ЮПЮ. А. Побединцева
Ю. А. Побединцева
A rare clinical observation of using hyperthermic isolated hepatic chemoperfusion is considered in the setting of a pathologically altered hepatic arterial blood flow in focal hepatic lesions caused by uveal melanoma metastases. The technical feasibility and safety of performing hyperthermic isolated hepatic chemoperfusion through the portal vein against the background of the altered hepatic arterial bed were demonstrated.

1 June 2022 in Creative surgery and oncology
Verified
Journal Article
Open access
PDF file
AKAndrei Kaprin
Andrei Kaprin
VUV. M. Unguryan
V. M. Unguryan
LPL. O. Petrov
L. O. Petrov
SIS. A. Ivanov
S. A. Ivanov
VNV. V. Nazarova
V. V. Nazarova
ЮПЮ. А. Побединцева
Ю. А. Побединцева
Background. Metastatic liver injury is a distinct oncological problem, irrespective of primary malignancy. Resection surgery is not always feasible in such patients. Isolated liver chemoperfusion is a promising treatment option in multiple small-focal metastatic organic lesions. This technique is technically complex, which limits its broader evaluation and adoption in clinical practice. The diversity of isolated liver chemoperfusion techniques does not allow an adequate assessment of world experience and requires further research. The important considerations with introducing isolated liver chemoperfusion are: an optimal surgical technique, liver isolation control method, as well as physiological arterial and portal blood flow maintenance.Materials and methods. A total of 21 patients were surveyed over June 2020 — December 2021. The patients were divided into 3 prospective cohorts: A) arteriocaval chemoperfusion, midline laparotomy access, technical-guided liver isolation, B) arteriocaval chemoperfusion, “in J laparotomy” access, ICG-guided liver isolation, C) arterio-porto-caval chemoperfusion, “in J laparotomy” access, ICG-guided liver isolation. A procedure’s tolerance was assessed with: the duration of surgery, postoperative ICU bed-days, total postoperative bed-days, hepatic cytolysis rates, chemotherapy side-effects severity.Results and discussion. The duration of surgery shortened with “in J laparotomy”. Haemotoxicity did not differ between cohorts A and B, albeit appearing significantly lower in cohort C. The cytolytic syndrome duration statistically significantly reduced in C vs. A and B cohorts.Conclusion. All the isolated liver chemoperfusion techniques employed are patient-safe. In ICG-guided liver isolation, the agent leakage into systemic blood flow is less likely, indicating a lower haemotoxicity. Arterioportal isolated chemoperfusion is more physiological compared to other techniques, thus facilitating lower hepatotoxicity. The use of “in J laparotomy” significantly reduces liver mobilisation and vascular cannulation times.